Cocrystal Pharma Inc. has released an investor presentation detailing its advancements in developing potent antivirals targeting serious diseases, including influenza, norovirus, and coronavirus. The company utilizes a proprietary drug discovery platform developed with Nobel Prize-winning technology to create broad-spectrum antiviral drugs. Current programs include an oral influenza PB2 inhibitor (CC-42344), progressing in Phase 2a studies, and a dual oral norovirus and coronavirus protease inhibitor (CDI-988), which has completed Phase 1 studies. Cocrystal Pharma is also exploring collaboration opportunities for pandemic preparedness and is led by a seasoned team including Nobel laureates. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。